{
  "label": "clinical_signal_03_ep_023",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:ace01eb11bd178d41631a87820db3d0b38695724566df0e4cf754bd0d2a63a06",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:55:21.345035",
  "content": "## 2024-08-05 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 210\n- Active: 196\n- Screen Failures Cumulative: 58\n- Withdrawals Cumulative: 14\n\n#### Sites\n- Site 01 Enrolled: 21\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 7\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 19\n- Site 03 Active: 19\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 17\n- Site 05 Active: 17\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 12\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 23\n- Site 07 Active: 22\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 16\n- Site 08 Active: 15\n- Site 08 Statin Concomitant: 5\n- Site 09 Enrolled: 17\n- Site 09 Active: 17\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 19\n- Site 11 Active: 18\n- Site 11 Statin Concomitant: 4\n- Site 12 Enrolled: 16\n- Site 12 Active: 15\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 127.9\n- ALT (U/L) Median: 125.2\n- AST (U/L) Mean: 91.5\n- AST (U/L) Median: 91.0\n- Bilirubin (mg/dL) Mean: 1.92\n- Bilirubin (mg/dL) Median: 1.9\n- ALP (U/L) Mean: 64.0\n- ALP (U/L) Median: 73.5\n- Creatinine (mg/dL) Mean: 0.95\n- Creatinine (mg/dL) Median: 0.91\n- BUN (mg/dL) Mean: 13.8\n- BUN (mg/dL) Median: 11.3\n- WBC (K) Mean: 6.7\n- WBC (K) Median: 6.4\n- Platelets (K) Mean: 257\n- Platelets (K) Median: 235\n\n#### Non-Statin Subgroup\n- N: 127\n- ALT (U/L) Mean: 27.9\n- ALT (U/L) Median: 27.8\n- AST (U/L) Mean: 27.3\n- AST (U/L) Median: 26.0\n- Bilirubin (mg/dL) Mean: 0.51\n- Bilirubin (mg/dL) Median: 0.49\n- ALP (U/L) Mean: 61.8\n- ALP (U/L) Median: 54.5\n- Creatinine (mg/dL) Mean: 0.94\n- Creatinine (mg/dL) Median: 0.81\n- BUN (mg/dL) Mean: 16.2\n- BUN (mg/dL) Median: 14.7\n- WBC (K) Mean: 7.7\n- WBC (K) Median: 7.0\n- Platelets (K) Mean: 231\n- Platelets (K) Median: 214\n\n### Adverse Events\n- AE ID: AE-0089, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0090, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0091, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0092, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0093, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0094, Description: drug-induced liver injury, Grade: 3, Relatedness: definitely related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 55\n- ACE Inhibitor Count: 29\n- Metformin Count: 21\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-047, Description: Missed visit window (2 days late), Severity: minor, Site: site_11\n\n### Investigator Notes\n- Training log updated for new study coordinator\n- Lab kits inventory adequate for next 4 weeks\n- No new safety signals identified this week by local PI\n- PK sub-study interim: LNS-4821 plasma concentration data consistent with CYP3A4 inhibition; atorvastatin AUC 3.2x in co-administered subjects\n\n### Events\n- CRO quarterly oversight report submitted\n- Drug accountability audit at Site 04: no discrepancies\n- PK sub-study interim data package distributed to DSMB members\n\n### Notes\n- Week 23: PK data supports CYP3A4 inhibition mechanism. Statin subgroup ALT 3-4x ULN.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_023",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-08-05T10:00:00",
    "phase": "root_cause",
    "signal_density": "high",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}